Although the extent to which tumour cells including malignant gliomas meet their cholesterol requirement is not fully understood, FASN and LDLR are potential targets for therapeutic intervention to circumvent tumour heterogeneity in HGGs [16,20]. The gene discussed is LDLR; the disease is malignant glioma.